A. Weber

Systemic IFN-β treatment induces apoptosis of peripheral immune cells in MS patients

Frauke Zipp, Judith Bellmann-Strobl, F. Zipp, 2003, Journal of Neuroimmunology.

TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis

J. Lünemann, K. Wernecke, F. Zipp, 2003, The Lancet.

Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans.

J. Ilonen, M. Ban, A. Goris, 2006 .

A genome-wide German screen for linkage disequilibrium in multiple sclerosis

S. Sawcer, A. Compston, F. Zipp, 2003, Journal of Neuroimmunology.

Frequency of blood CX3CR1‐positive natural killer cells correlates with disease activity in multiple sclerosis patients

J. Wuerfel, F. Zipp, J. Bellmann-Strobl, 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Investigation of bax, bcl-2, bcl-x and p53 gene polymorphisms in multiple sclerosis

W. Brück, F. Zipp, T. Kuhlmann, 2002, Journal of Neuroimmunology.

Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity

G. Salemi, M. Trojano, G. Edan, 2005, Neurology.

Identification and functional characterization of a highly polymorphic region in the human TRAIL promoter in multiple sclerosis

T. Wienker, W. Brück, F. Zipp, 2004, Journal of Neuroimmunology.

Elevated Bcl-XL levels correlate with T cell survival in multiple sclerosis

J. Lünemann, F. Zipp, S. Waiczies, 2002, Journal of Neuroimmunology.

The multiple sclerosis severity score

S. Sawcer, X. Montalban, E. Celius, 2003 .